Tirzepatide denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Tirzepatide as Not FDA-Approved

A not-FDA-approved denial typically means one of two things: either Aetna's system has flagged the specific indication on your claim as outside the drug's FDA-approved labeling (an off-label use), or there is an administrative error in how the diagnosis or indication was coded on the prior authorization submission.

Before assuming this is a substantive clinical denial, verify with your prescriber's office that the diagnosis code submitted precisely matches an FDA-approved indication for tirzepatide. If there was a coding mismatch, a corrected resubmission may resolve the denial without a formal appeal. If the indication is genuinely off-label, a formal appeal with supporting clinical literature is the appropriate path.

## Your Appeal Rights

• ACA §2719 / ERISA §503: Federal law requires full-and-fair internal review and access to independent external review for most non-grandfathered plans.
• Internal appeal deadline: Generally 180 days from the denial notice; check your Explanation of Benefits for the exact cutoff.
• External review window: Approximately four months after a final internal denial to request independent review.
• Expedited review: Available for urgent conditions; request in writing with your internal appeal.

## Documentation to Gather

1. FDA prescribing information: Obtain the current FDA-approved label for tirzepatide. Identify the exact approved indication(s) and confirm your prescription is written for one of them — or, if off-label, acknowledge that clearly. 2. Diagnosis and coding verification: Confirm with your prescriber's office the exact ICD-10 code submitted. Request a copy of the prior authorization submission and verify the diagnosis code matches the approved indication. 3. Clinical chart documentation: Current visit notes confirming your diagnosis in terms that align with the FDA-approved indication language. 4. Prescriber medical-necessity letter: If the use is on-label, the letter should state that plainly and reference the FDA-approved indication by name. If it is off-label, the letter should cite published clinical guidance from a recognized professional organization (e.g., the applicable ADA or endocrine society guidelines) supporting the use. 5. Insurer policy mapping: Pull Aetna's current published clinical policy and address every listed criterion in your submission.

## Criteria-Mapping Structure

Organize your rebuttal as: Aetna's basis for not-approved determination (quoted from the denial) | FDA label section and language | How your claim aligns with approved use. If a coding error is the root cause, attach a corrected prior authorization form alongside the appeal to prevent further processing delays.

Always verify the most current FDA-approved indications directly from the official prescribing information, and confirm Aetna's current policy version, before submitting — both documents are updated periodically.